 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy of the PARP inhibitor Pamiparib as a single agent in the treatment of platinum-sensitive/resistant ovarian cancer

Clin Cancer Res: Efficacy of the PARP inhibitor Pamiparib as a single agent in the treatment of platinum-sensitive/resistant ovarian cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

shrimp allergy treatment

sennosides 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

PARP1/2 protein is involved in the repair of DNA single-strand and double-strand breaks
.

Normal cells repair broken DNA through base-pairing repair and homologous recombination (HR) pathways; HR-deficient (HRD) cancer cells cannot repair broken double-stranded DNA

Pamiparib is a potential selective oral PARP1/2 inhibitor
.

The results of a phase I study of a phase I/II study conducted in China showed that Pamiparib (60 mg bid) has anti-tumor activity and acceptable safety in patients with advanced cancers (including epithelial ovarian cancer [OC]) in China

Ovarian cancer

The study recruited patients with platinum-sensitive ovarian cancer (PSOC, no disease progression within 6 months after the last platinum treatment) or platinum-resistant ovarian cancer (PROC, progression 6 months after platinum treatment) who were 18 years of age or older
.

The test patient carries a pathogenic or possibly pathogenic germline BRCA mutation (gBRCA ^mut ), and the previous treatment does not exceed 2 lines

^mut

Treatment response of PSOC patients

A total of 113 patients (PSOC 90, PROC 23) were recruited.
The median age was 54 years (range 34-79).
25.
6% of the patients received ≥4 previous systemic chemotherapy
.

The median follow-up was 12.

82 PSOC patients and 19 PROC patients were included in the efficacy evaluation

Treatment response of PROC patients

The most common side effects ≥ grade 3 are hematological toxicity, including anemia and decreased neutrophil count

In summary, Pamiparib 60 mg bid has shown longer-lasting anti-tumor activity in patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer carrying gBRCAmut , and its safety is controllable

Pamiparib 60 mg bid showed longer-lasting anti-tumor activity in patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer carrying gBRCAmut.

Original source:

Xiaohua Wu, Jianqing Zhu, Jing Wang, et al.

Pamiparib Monotherapy for Patients With Germline BRCA1 / 2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.